Chaobin He

List of Publications by Year
in descending order

45	723	516215 16	642321 23
papers	citations	h-index	g-index

48	48	48	1068
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Progression Patterns and Post-Progression Survival in Recurred Intrahepatic Cholangiocarcinoma Patients: A Novel Prognostic Nomogram Based on Multicenter Cohorts. Frontiers in Oncology, 2022, 12, 832038.	1.3	0
2	The role of irreversible electroporation in promoting M1 macrophage polarization via regulating the HMGB1-RAGE-MAPK axis in pancreatic cancer. OncoImmunology, 2021, 10, 1897295.	2.1	29
3	Integrated Bioinformatic Analysis of SARS-CoV-2 Infection Related Genes ACE2, BSG and TMPRSS2 in Aerodigestive Cancers. Journal of Inflammation Research, 2021, Volume 14, 791-802.	1.6	15
4	Identification of Circulating Biomarkers and Construction of a Prognostic Signature for Survival Prediction in Locally Advanced Pancreatic Cancer After Irreversible Electroporation. Journal of Inflammation Research, 2021, Volume 14, 1689-1699.	1.6	1
5	Survival Comparisons of Hepatic Arterial Infusion Chemotherapy With mFOLFOX and Transarterial Chemoembolization in Patients With Unresectable Intrahepatic Cholangiocarcinoma. Frontiers in Oncology, 2021, 11, 611118.	1.3	14
6	The impact of different metastatic patterns on survival in patients with pancreatic cancer. Pancreatology, 2021, 21, 556-563.	0.5	16
7	Combining NanoKnife with M1 oncolytic virus enhances anticancer activity in pancreatic cancer. Cancer Letters, 2021, 502, 9-24.	3.2	30
8	An Inflammation-Index Signature Predicts Prognosis of Patients with Intrahepatic Cholangiocarcinoma After Curative Resection. Journal of Inflammation Research, 2021, Volume 14, 1859-1872.	1.6	4
9	Evaluation of Preoperative Inflammation-Based Prognostic Scores in Patients With Intrahepatic Cholangiocarcinoma: A Multicenter Cohort Study. Frontiers in Oncology, 2021, 11, 672607.	1.3	1
10	Irreversible Electroporation Plus Anti-PD-1 Antibody versus Irreversible Electroporation Alone for Patients with Locally Advanced Pancreatic Cancer. Journal of Inflammation Research, 2021, Volume 14, 4795-4807.	1.6	16
11	Comparative Recurrence Analysis of Pancreatic Adenocarcinoma after Resection. Journal of Oncology, 2021, 2021, 1-18.	0.6	3
12	Score for the Survival Probability of Patients With Orbital Rhabdomyosarcoma After Surgery: A Long-Term and Large Cohort Study. Frontiers in Oncology, 2020, 10, 1590.	1.3	1
13	The prognostic significance of inflammation-based scores in patients with ampullary carcinoma after pancreaticoduodenectomy. BMC Cancer, 2020, 20, 981.	1.1	8
14	Bioinformatic Analysis of Correlation between Immune Infiltration and COVID-19 in Cancer Patients. International Journal of Biological Sciences, 2020, 16, 2464-2476.	2.6	13
15	A Novel Nomogram to Predict Survival in Patients With Recurrence of Pancreatic Ductal Adenocarcinoma After Radical Resection. Frontiers in Oncology, 2020, 10, 1564.	1.3	5
16	SYPL1 Inhibits Apoptosis in Pancreatic Ductal Adenocarcinoma via Suppression of ROS-Induced ERK Activation. Frontiers in Oncology, 2020, 10, 1482.	1.3	17
17	Score for the Overall Survival Probability of Patients With Pancreatic Adenocarcinoma of the Body and Tail After Surgery: A Novel Nomogram-Based Risk Assessment. Frontiers in Oncology, 2020, 10, 590.	1.3	7
18	Comparison of combination therapies in the management of locally advanced pancreatic cancer: Induction chemotherapy followed by irreversible electroporation vs radiofrequency ablation. Cancer Medicine, 2020, 9, 4699-4710.	1.3	11

#	Article	IF	Citations
19	Tâ€cell activation and immune memory enhancement induced by irreversible electroporation in pancreatic cancer. Clinical and Translational Medicine, 2020, 10, e39.	1.7	46
20	Oxidative stress induces monocyteâ€toâ€myofibroblast transdifferentiation through p38 in pancreatic ductal adenocarcinoma. Clinical and Translational Medicine, 2020, 10, e41.	1.7	34
21	Irreversible electroporation after induction chemotherapy versus chemotherapy alone for patients with locally advanced pancreatic cancer: A propensity score matching analysis. Pancreatology, 2020, 20, 477-484.	0.5	21
22	A Novel Prediction Tool Based on Large Cohorts to Determine the Cancer-Specific Survival Probability of Patients With Locally Advanced Pancreatic Cancer After Irreversible Electroporation Treatment. Frontiers in Oncology, 2020, 10, 952.	1.3	2
23	Comparison of Survival Between Irreversible Electroporation Followed by Chemotherapy and Chemotherapy Alone for Locally Advanced Pancreatic Cancer. Frontiers in Oncology, 2020, 10, 6.	1.3	14
24	Induced CD10 expression during monocyte-to-macrophage differentiation identifies a unique subset of macrophages in pancreatic ductal adenocarcinoma. Biochemical and Biophysical Research Communications, 2020, 524, 1064-1071.	1.0	21
25	Survival Comparison of Neoadjuvant Chemotherapy Followed by Irreversible Electroporation Versus Conversional Resection for Locally Advanced Pancreatic Cancer. Frontiers in Oncology, 2020, 10, 622318.	1.3	6
26	A feasible CT feature to differentiate focalâ€type autoimmune pancreatitis from pancreatic ductal adenocarcinoma. Cancer Medicine, 2019, 8, 6250-6257.	1.3	5
27	Development and validation of a nomogram to predict liver metastasis in patients with pancreatic ductal adenocarcinoma: a large cohort study . Cancer Management and Research, 2019, Volume 11, 3981-3991.	0.9	15
28	Effect of prior cancer on survival outcomes for patients with pancreatic adenocarcinoma: a propensity score analysis. BMC Cancer, 2019, 19, 509.	1.1	16
29	Immunomodulatory Effect after Irreversible Electroporation in Patients with Locally Advanced Pancreatic Cancer. Journal of Oncology, 2019, 2019, 1-13.	0.6	38
30	Irreversible electroporation versus radiotherapy after induction chemotherapy on survival in patients with locally advanced pancreatic cancer: a propensity score analysis. BMC Cancer, 2019, 19, 394.	1.1	28
31	Competing risk analyses of overall survival and cancer-specific survival in patients with combined hepatocellular cholangiocarcinoma after surgery. BMC Cancer, 2019, 19, 178.	1.1	16
32	The prognostic and predictive value of the combination of the neutrophil-to-lymphocyte ratio and the platelet-to-lymphocyte ratio in patients with hepatocellular carcinoma who receive transarterial chemoembolization therapy . Cancer Management and Research, 2019, Volume 11, 1391-1400.	0.9	27
33	A Quantitative Clinicopathological Signature for Predicting Recurrence Risk of Pancreatic Ductal Adenocarcinoma After Radical Resection. Frontiers in Oncology, 2019, 9, 1197.	1.3	12
34	Prognostic Model to Predict Cancer-Specific Survival for Patients With Gallbladder Carcinoma After Surgery: A Population-Based Analysis. Frontiers in Oncology, 2019, 9, 1329.	1.3	26
35	Irreversible electroporation followed by chemotherapy vs. chemotherapy alone for locally advanced pancreatic cancer: A large cohort propensity score analysis.. Journal of Global Oncology, 2019, 5, 117-117.	0.5	0
36	The Predictive Value of Staging Systems and Inflammation Scores for Patients with Combined Hepatocellular Cholangiocarcinoma After Surgical Resection: a Retrospective Study. Journal of Gastrointestinal Surgery, 2018, 22, 1239-1250.	0.9	23

#	Article	IF	Citations
37	Increased Overall Survival and Decreased Cancer-Specific Mortality in Patients with Hepatocellular Carcinoma Treated by Transarterial Chemoembolization and Human Adenovirus Type-5 Combination Therapy: a Competing Risk Analysis. Journal of Gastrointestinal Surgery, 2018, 22, 989-997.	0.9	9
38	Neutrophil-to-lymphocyte ratio predicts overall survival of patients with combined hepatocellular cholangiocarcinoma. Oncology Letters, 2018, 15, 4262-4268.	0.8	9
39	Nomogram to predict cancer-specific survival in patients with pancreatic acinar cell carcinoma: A competing risk analysis. Annals of Oncology, 2018, 29, ix60.	0.6	0
40	Nomogram to Predict Cancer-Specific Survival in Patients with Pancreatic Acinar Cell Carcinoma: A Competing Risk Analysis. Journal of Cancer, 2018, 9, 4117-4127.	1.2	23
41	A Refined Staging Model for Resectable Pancreatic Ductal Adenocarcinoma Incorporating Examined Lymph Nodes, Location of Tumor and Positive Lymph Nodes Ratio. Journal of Cancer, 2018, 9, 3507-3514.	1.2	12
42	Preoperative CEA levels are supplementary to CA19-9 levels in predicting prognosis in patients with resectable intrahepatic cholangiocarcinoma. Journal of Cancer, 2018, 9, 3117-3128.	1.2	35
43	Overall survival and cancer-specific survival in patients with surgically resected pancreatic head adenocarcinoma: A competing risk nomogram analysis. Journal of Cancer, 2018, 9, 3156-3167.	1.2	43
44	Surgical management of periampullary adenocarcinoma: defining an optimal prognostic lymph node stratification schema. Journal of Cancer, 2018, 9, 1667-1679.	1.2	18
45	Nomograms predict long-term survival for patients with periampullary adenocarcinoma after pancreatoduodenectomy. BMC Cancer, 2018, 18, 327.	1.1	33